Insert Therapeutics

From Wikipedia, the free encyclopedia

Insert Therapeutics is a medical research company that uses nanobiotechnology specializing in therapeutic agents that are conjugated, so as to facilitate and enhance drug delivery. The small company was founded in 2000, is located in Pasadena, California, and majority-owned by Arrowhead Research Corporation.

The conjugates consist of a cyclodextrin-containing polymer (Cyclosert) that acts as a drug delivery system, and a linked medication, such as a chemotherapeutic drug of already proven efficacy.[1] The size of the polymer is designed to “fit” the specific target, as vessels in a neoplasm allow for leakage of different size of polymers, as in healthy tissue. The leaked conjugates are concentrated in the target area. As a result chemotherapeutic activity is locally enhanced, while general side effects are decreased.[1]

Currently IT-101 is investigated in a clinical trial.[1]

[edit] References

  1. ^ a b c IT-101 trial

[edit] External links